cetuximab
Start here
Neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is evolving from conventional chemotherapy toward immunotherapy-integrated regimens; 65-70% of patients present with stage III-IVA locally advanced disease at diagnosis. Current standards include surgery followed by adjuvant cisplatin-based chemoradiotherapy or definitive concurrent chemoradiotherapy, with cetuximab plus radiotherapy for HPV-negative patients unfit for platinum. Traditional induction regimens combine paclitaxel, platinum and 5-fluorouracil with radiotherapy, and early-phase trials are evaluating immune checkpoint inhibitors to improve organ preservation and tumor control.
Excerpted from Oncol Rep
Coverage timeline
Follow the coverage to see the different angles.
- Oncol RepAdvances in neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (Review)
Neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is evolving from conventional chemotherapy toward immunotherapy-integrated regimens; 65-70% of patients present with stage III-IVA locally advanced disease at diagnosis. Current standards include surgery followed by adjuvant cisplatin-based chemoradiotherapy or definitive concurrent chemoradiotherapy, with cetuximab plus radiotherapy for HPV-negative patients unfit for platinum. Traditional induction regimens combine paclitaxel, platinum and 5-fluorouracil with radiotherapy, and early-phase trials are evaluating immune checkpoint inhibitors to improve organ preservation and tumor control.
- biorxiv.orgPickMalignant and stromal partial EMT programmes and cetuximab outcome in head and neck cancer
Standard bulk partial EMT (pEMT) scores in head and neck squamous cell carcinoma mainly measure stroma: across three single-cell datasets, the malignant arm (laminin-332 and hemidesmosome genes) sat in malignant cells while the stromal arm (fibrillar collagens, vimentin) sat in fibroblasts. A classifier and 12-gene core recovering the malignant arm predicted long progression-free survival in 40 patients given platinum and cetuximab (AUC 0.78 and 0.82), but the malignant arm tracked the Basal subtype, whose score performed as well or better (0.93) and also in two xenograft panels.
Heat trend for this story
Heat now 20·Peak in the comparable set 30 (Oct 24 22:00)·Change over 24h in the comparable set –·Participants now 3
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.